Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 25


Overexpression of ABCB1 Transporter Confers Resistance to mTOR Inhibitor WYE-354 in Cancer Cells.

Wang J, Yang DH, Yang Y, Wang JQ, Cai CY, Lei ZN, Teng QX, Wu ZX, Zhao L, Chen ZS.

Int J Mol Sci. 2020 Feb 19;21(4). pii: E1387. doi: 10.3390/ijms21041387.


Venetoclax, a BCL-2 Inhibitor, Enhances the Efficacy of Chemotherapeutic Agents in Wild-Type ABCG2-Overexpression-Mediated MDR Cancer Cells.

Wang JQ, Li JY, Teng QX, Lei ZN, Ji N, Cui Q, Zeng L, Pan Y, Yang DH, Chen ZS.

Cancers (Basel). 2020 Feb 18;12(2). pii: E466. doi: 10.3390/cancers12020466.


Biological evaluation of non-basic chalcone CYB-2 as a dual ABCG2/ABCB1 inhibitor.

Cai CY, Zhang W, Wang JQ, Lei ZN, Zhang YK, Wang YJ, Gupta P, Tan CP, Wang B, Chen ZS.

Biochem Pharmacol. 2020 Feb 7:113848. doi: 10.1016/j.bcp.2020.113848. [Epub ahead of print]


Tivantinib, A c-Met Inhibitor in Clinical Trials, Is Susceptible to ABCG2-Mediated Drug Resistance.

Wu ZX, Yang Y, Teng QX, Wang JQ, Lei ZN, Wang JQ, Lusvarghi S, Ambudkar SV, Yang DH, Chen ZS.

Cancers (Basel). 2020 Jan 12;12(1). pii: E186. doi: 10.3390/cancers12010186.


Tetrandrine Interaction with ABCB1 Reverses Multidrug Resistance in Cancer Cells Through Competition with Anti-Cancer Drugs Followed by Downregulation of ABCB1 Expression.

Liao D, Zhang W, Gupta P, Lei ZN, Wang JQ, Cai CY, Vera AA, Zhang L, Chen ZS, Yang DH.

Molecules. 2019 Nov 30;24(23). pii: E4383. doi: 10.3390/molecules24234383.


Derivative of 5-cyano-6-phenylpyrimidin antagonizes ABCB1- and ABCG2-mediated multidrug resistance.

Wang JQ, Wang B, Lei ZN, Teng QX, Li JY, Zhang W, Ji N, Cai CY, Ma LY, Liu HM, Chen ZS.

Eur J Pharmacol. 2019 Nov 15;863:172611. doi: 10.1016/j.ejphar.2019.172611. Epub 2019 Aug 30.


Fexofenadine inhibits TNF signaling through targeting to cytosolic phospholipase A2 and is therapeutic against inflammatory arthritis.

Liu R, Chen Y, Fu W, Wang S, Cui Y, Zhao X, Lei ZN, Hettinghouse A, Liu J, Wang C, Zhang C, Bi Y, Xiao G, Chen ZS, Liu CJ.

Ann Rheum Dis. 2019 Nov;78(11):1524-1535. doi: 10.1136/annrheumdis-2019-215543. Epub 2019 Jul 13.


Benzoyl indoles with metabolic stability as reversal agents for ABCG2-mediated multidrug resistance.

Cai CY, Zhai H, Lei ZN, Tan CP, Chen BL, Du ZY, Wang JQ, Zhang YK, Wang YJ, Gupta P, Wang B, Chen ZS.

Eur J Med Chem. 2019 Oct 1;179:849-862. doi: 10.1016/j.ejmech.2019.06.066. Epub 2019 Jun 24.


Midostaurin Reverses ABCB1-Mediated Multidrug Resistance, an in vitro Study.

Ji N, Yang Y, Cai CY, Wang JQ, Lei ZN, Wu ZX, Cui Q, Yang DH, Chen ZS, Kong D.

Front Oncol. 2019 Jun 18;9:514. doi: 10.3389/fonc.2019.00514. eCollection 2019.


Tepotinib reverses ABCB1-mediated multidrug resistance in cancer cells.

Wu ZX, Teng QX, Cai CY, Wang JQ, Lei ZN, Yang Y, Fan YF, Zhang JY, Li J, Chen ZS.

Biochem Pharmacol. 2019 Aug;166:120-127. doi: 10.1016/j.bcp.2019.05.015. Epub 2019 May 9.


Colchicine Binding Site Agent DJ95 Overcomes Drug Resistance and Exhibits Antitumor Efficacy.

Arnst KE, Wang Y, Lei ZN, Hwang DJ, Kumar G, Ma D, Parke DN, Chen Q, Yang J, White SW, Seagroves TN, Chen ZS, Miller DD, Li W.

Mol Pharmacol. 2019 Jul;96(1):73-89. doi: 10.1124/mol.118.114801. Epub 2019 May 1.


Y6, an Epigallocatechin Gallate Derivative, Reverses ABCG2-Mediated Mitoxantrone Resistance.

Zhao RQ, Wen Y, Gupta P, Lei ZN, Cai CY, Liang G, Yang DH, Chen ZS, Xie YA.

Front Pharmacol. 2019 Jan 10;9:1545. doi: 10.3389/fphar.2018.01545. eCollection 2018.


Ulixertinib (BVD-523) antagonizes ABCB1- and ABCG2-mediated chemotherapeutic drug resistance.

Ji N, Yang Y, Lei ZN, Cai CY, Wang JQ, Gupta P, Xian X, Yang DH, Kong D, Chen ZS.

Biochem Pharmacol. 2018 Dec;158:274-285. doi: 10.1016/j.bcp.2018.10.028. Epub 2018 Oct 26.


VS-4718 Antagonizes Multidrug Resistance in ABCB1- and ABCG2-Overexpressing Cancer Cells by Inhibiting the Efflux Function of ABC Transporters.

Ji N, Yang Y, Cai CY, Lei ZN, Wang JQ, Gupta P, Teng QX, Chen ZS, Kong D, Yang DH.

Front Pharmacol. 2018 Oct 30;9:1236. doi: 10.3389/fphar.2018.01236. eCollection 2018.


Regorafenib antagonizes BCRP-mediated multidrug resistance in colon cancer.

Zhang YK, Wang YJ, Lei ZN, Zhang GN, Zhang XY, Wang DS, Al-Rihani SB, Shukla S, Ambudkar SV, Kaddoumi A, Shi Z, Chen ZS.

Cancer Lett. 2019 Feb 1;442:104-112. doi: 10.1016/j.canlet.2018.10.032. Epub 2018 Oct 28.


Olmutinib (BI1482694/HM61713), a Novel Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor, Reverses ABCG2-Mediated Multidrug Resistance in Cancer Cells.

Zhang W, Fan YF, Cai CY, Wang JQ, Teng QX, Lei ZN, Zeng L, Gupta P, Chen ZS.

Front Pharmacol. 2018 Oct 9;9:1097. doi: 10.3389/fphar.2018.01097. eCollection 2018.


Selonsertib (GS-4997), an ASK1 inhibitor, antagonizes multidrug resistance in ABCB1- and ABCG2-overexpressing cancer cells.

Ji N, Yang Y, Cai CY, Lei ZN, Wang JQ, Gupta P, Shukla S, Ambudkar SV, Kong D, Chen ZS.

Cancer Lett. 2019 Jan;440-441:82-93. doi: 10.1016/j.canlet.2018.10.007. Epub 2018 Oct 10.


Design, synthesis and biological evaluation of selective survivin inhibitors.

Xiao M, Xue Y, Wu Z, Lei ZN, Wang J, Chen ZS, Li W.

J Biomed Res. 2019 Apr 22;33(2):82-100. doi: 10.7555/JBR.31.20160173.


Discovery of 5-Cyano-6-phenylpyrimidin Derivatives Containing an Acylurea Moiety as Orally Bioavailable Reversal Agents against P-Glycoprotein-Mediated Mutidrug Resistance.

Wang B, Ma LY, Wang JQ, Lei ZN, Gupta P, Zhao YD, Li ZH, Liu Y, Zhang XH, Li YN, Zhao B, Chen ZS, Liu HM.

J Med Chem. 2018 Jul 26;61(14):5988-6001. doi: 10.1021/acs.jmedchem.8b00335. Epub 2018 Jul 18.


Synthesis and biological evaluation of indole-based UC-112 analogs as potent and selective survivin inhibitors.

Wang Q, Arnst KE, Xue Y, Lei ZN, Ma D, Chen ZS, Miller DD, Li W.

Eur J Med Chem. 2018 Apr 10;149:211-224. doi: 10.1016/j.ejmech.2018.02.045. Epub 2018 Feb 19.

Supplemental Content

Loading ...
Support Center